Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss

Stock Track

02-27

Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.

For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.

For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1182259989"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182259989\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1182259989?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182259989","market":"us","top_or_hot":-1,"title":"Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss","media":"Stock Track","content":"<p>Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.</p>\n\n<p>For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.</p>\n\n<p>For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.</p>\n\n<p>For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.</p>\n\n<p>For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GDRX","symbol_name":"GoodRx Holdings, Inc.","start_time":0,"source_url":"","article_id":"1182259989","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182259989","pubTimestamp":1740667601,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GoodRx Holdings Inc.  surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GDRX":"GoodRx Holdings, Inc."},"translate_title":"尽管第四季度业绩不佳，但由于2025年前景乐观，GoodRx股价盘前飙升5.5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDRX":1},"content_text":"Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.\nFor the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.\nFor the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}